# Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia

> **NCT00006400** · PHASE3 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 193 (actual)

## Conditions studied

- Hematologic Diseases
- Anemia, Sickle Cell

## Interventions

- **DRUG:** Hydroxyurea
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00006400
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 193 (ACTUAL)
- **Last updated:** 2020-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006400, "Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00006400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*